.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean consequence of 11 months, individuals with metastatic intestinal lumps that obtained biomarker-matched treatments based upon circulating tumor DNA profiling showed a higher clinical advantage than those receiving unparalleled therapy.